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ABSTRACT
OBJECTIVE: Glial cell line-derived neurotrophic factor (GDNF), being a protective of
dopaminergic neurons, is reported to modulate addictive behaviours and have a role as a
negative regulator for biochemical and behavioural adaptations to drug abuse. We aimed to
reveal impulsivity and serum GDNF levels in patients with heroin addiction and investigate
their relationships in order to contribute to the understanding of behavioural aspects and
biological mechanisms in heroin addiction via this study.
METHODS: This study was performed at the Department of Psychiatry of Ankara Numune
Training and Research Hospital, Turkey. We recruited 129 heroin-dependent patients and 90
age, sex, and smoking-matched healthy controls with no major psychopathology. Barratt
Impulsivity Scale-11, Hospital Anxiety and Depression Scale (HADS) and sociodemographic
data form were applied to all participants. Laboratory analysis for serum GDNF levels was
performed for each participant’s blood sample.
RESULTS: Total impulsivity scores and scores of Attentional Impulsivity, Motor Impulsivity, and
Unplanned Impulsivity subscales were all higher in heroin addicts compared to the controls.
Heroin addicts had also lower serum GDNF levels and lower GDNF levels were associated
with high impulsivity and high HADS scores in heroin addicts.
CONCLUSION: Decrement in GDNF levels in heroin addiction seems as to be an important data
which could be associated with impulsivity, anxiety, and depressive symptoms. GDNF could find
a prominent place among the target molecules in the treatment of heroin addiction.
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Introduction
Neurotrophic factors have an important role in the
growth and differentiation of neurons during develop-
ment and have been implicated in many forms of plas-
ticity within the adult central nervous system.
The glial cell line-derived neurotrophic factor
(GDNF) is one of the most potent neurotrophic factors
influencing the dopaminergic system. It is reported
that GDNF has distinct protective effects on the survi-
val of midbrain dopaminergic neurons in both in vitro
and in vivo studies [1–4]. Preclinic studies demon-
strated that GDNF was protective of dopaminergic
neurons when administered in advance of degenerative
toxins, and it also may have restorative effects on dying
dopaminergic neurons [5].
Neurotrophic factors and especially GDNF have
raised considerable hope to be able to stop the pro-
gressive degeneration in neuropsychiatric diseases
such as Parkinson Disease and Alzheimer Disease
[6]. Besides, animal studies indicate that GDNF modu-
lates addictive behaviours and the role of GDNF as a
negative regulator for biochemical and behavioural
adaptations to drug abuse was reported [7]. Opiate
withdrawal was shown to regulate the expression levels
of several neurotrophic factors in specific regions of
adult brain [8]. The rewarding effects and/or self-
administration of cocaine and ethanol were found to
be associated with up-regulation of GDNF levels in
the ventral tegmental area (VTA) or striatum [9,10].
Messer et al. reported a functional interaction
between GDNF and drugs of abuse at the level of the
mesolimbic dopamine system and emphasized com-
plex mechanisms that were likely to be induced in
brain by chronic exposure to a drug of abuse [11].
Garnicella et al. found that GDNF was highly effec-
tive in reducing heavy alcohol drinking and GDNF in
VTA was more effective in inhibiting reacquisition of
ethanol self-administration after the extinction period
than in reducing ethanol self-administration before
the period of abstinence [12]. So, these findings were
stated to suggest an important protective role for
GDNF in abstinence and relapse processes.
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In light of these data, we aimed to search on GDNF
levels and heroin addiction which is a growing serious
health problem in the world. We focused on GDNF
because GDNF has so far more potent effects on the
survival and protection of dopaminergic neurons com-
pared to brain-derived neurotrophic factor (BDNF)
and other neurotrophins [3] and GDNF enhances the
survival of midbrain dopamine neurons in vivo after
being exposed to dopaminergic neurotoxins such as
6-hydroxydopamine in an obvious way [1]. Addition-
ally, it was shown that a single injection of GDNF
into the midbrain could exert protective effects for at
least a month [2,13].
Traits that are related to the extensive construct of
disinhibition such as sensation seeking, impulsivity,
and behavioural under control have been found to pre-
dict substance misuse disorders in adults and it is
reported to be higher in substance-dependent patients
[14,15].
Pompili et al. reported that substance-dependent
patients have higher hopelessness, global psycho-
pathology severity, impulsivity/aggression, and they
are frequently depressed [16].
As far as we know, there are no studies in the litera-
ture related to the association between GDNF levels,
impulsivity, and clinical characteristics in heroin-
dependent patients. Evidence-based data related to
impulsive personality traits to the development and
maintenance of substance misuse problems have been
rising [17–19].
We aimed to reveal impulsivity and serum GDNF
levels in patients with heroin addiction and investigate
their relationships in order to contribute the under-
standing of behavioural aspects and biological mechan-
isms in heroin addiction via this study.
Methods
Participants
This study was performed at the Department of Psy-
chiatry of Ankara Numune Training and Research
Hospital, Turkey. We recruited 129 heroin-dependent
patients who admitted to our addiction clinic between
January 2015 and May 2015; and 90 age, sex, and
smoking-matched healthy controls with no major
psychopathology.
Inclusion criteria for the heroin-dependent group
were a diagnosis of heroin dependence according to
the Diagnostic and Statistical Manual of Mental Dis-
orders, 5th edition, 18–65 years of age, and possessing
at least five years of primary school education.
The exclusion criteria included anoxia or hypoxia
during birth; the presence of a major medical disorder
or neuropsychiatric symptoms secondary to a meta-
bolic disorder or structural lesion and any comorbid
psychiatric disorders in the heroin-dependent group.
We did a cross-sectional study to investigate the
impulsivity and serum GDNF levels in heroin-depen-
dent patients. The study received approval by the
local ethics committee.
Every participant was examined by two trained psy-
chiatrists after obtaining informed consent. Sociode-
mographic data form and the Barratt Impulsiveness
Scale were applied to all participants.
Barratt Impulsivity Scale-11
The Barratt Impulsivity Scale (BIS) was developed by Bar-
ratt in 1959 and over time it has undergone many revi-
sions. The latest form-11 was developed in 1995 [20].
The scale consists of 30 items and 3 subscales: Attentional
Impulsivity (AI),Motor impulsivity (MI), andUnplanned
Impulsivity (UI). BIS evaluated four different sub-scores
obtained; total points, UI, AI, and MI. High BIS scores
are increased levels of the impulsivity index. Validity and
reliability study in Turkey was performed by Güleç et al.
in 2008 and they reported internal consistency rates
(Cronbach’s alpha) as 0.82 for total score, 0.80, 0.70, and
0.64 for UI, MI, and AI subscales, respectively [21]. In
this study, the scoring key suggested by Patton et al. was
used to evaluate the scale [20].
Sociodemographic data form
Sociodemographic data were used in order to describe
characteristics of patients and to determine differences
among the groups. The form included age, sex, birth
place, living place, education years, marital status,
family type, occupation, monthly income, history of
military service, history of prison, self and family his-
tory of physical and psychiatric diseases, first adminis-
tration date, history of nicotine, alcohol, cannabis,
cocaine and other illicit drugs used, detailed history
of heroin usage (dosage, duration, dosage, etc.), and
history of addiction treatment trials.
Blood samples and laboratory analysis
With informed consent of patients, 10 cm3 of periph-
eral venous blood samples was taken, placed in gel-
containing tubes and centrifuged at 4000 rpm for
10 min to analyse the separated serum. Haemolysed
and icteric serums were not used in this study.
SerumGDNF levels were evaluated with a commercial
ELISA kit (BOSTER, Boster Biological Technology Co.
Ltd, Fremont, CA, Code: EK0362, LOT: 851034314901).
Its %CV value was <10, the measurement interval was
31.2–2000 pg/mL and sensitivity was <4 pg/mL.
Statistical analyse
All statistical analyses were performed with IBM SPSS
ver.22.0. The Shapiro Wilk test was used as the
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normality test. Continuous variables were the Mann–
Whitney U test when the data were not normally dis-
tributed. Categorical variables were compared using
Pearson’s chi-squared test, the Fisher–Freeman–
Halton test, and Fisher’s exact test. Correlations
between variables were tested using Spearman corr-
elation coefficients. A p-value <.05 was considered
as significant.
Results
Overall, 129 heroin addicts and 90 healthy controls
were enrolled. Demographic and clinical characteristics
of two groups are contrasted in Table 1. There were no
significant differences among the groups in age, gen-
der, educational level, occupation, marital status,
family construct, monthly income, and alcohol and
nicotine consumption. Family history of addiction
and history of prison rate were higher in the patient
group (p = .024 and p = .000 respectively).
Impulsivity
Total impulsivity scores and scores of AI, MI, and UI
subscales were all significantly higher in heroin addicts
as shown in Table 2.
GDNF
GDNF levels showed a significant statistical differ-
ence between heroin addicts and control groups
(p = .002). Heroin addicts had lower levels of GDNF
(mean ± SD:472.2 ± 272.7) compared to the control
group (mean ± SD:583.1 ± 235.2).
We tested correlations to analyse variables affecting
GDNF levels in heroin addicts and have found that
lower GDNF levels are associated with high impulsivity
and high Hospital Anxiety and Depression Scale-
Anxiety (HAD-A), Hospital Anxiety and Depression
Scale-Depression (HAD-D) scores (Figure 1).
There was an inverse correlation between serum
GDNF levels and both daily dosage of used heroin
(gram) and duration of addiction (Table 3).
Figure 1. Correlation between GDNF levels and total impulsivity in heroin addicts.
Table 1. Demographic characteristics of heroin addicts and
controls.
Variables
Heroin addicts
(n = 129) Controls (n = 90) p
Age, mean ± SD (min–max) 25.1± (17–46) 24.9± (17–47) >.05
Gender >.05
Male 119 (92.2%) 83 (92.2%)
Female 10 (7.8%) 7 (7.8%)
Education >.05
Primary School 92 (71.9%) 47 (65.3%)
High School 28 (21.9%) 19 (26.4%)
College/University 8 (6.3%) 6 (8.3%)
Marital Status >.05
Married 25 (74.4%) 45 (65.2%)
Single 96 (19.4%) 18 (26.1%)
Divorced 8 (6.2%) 6 (8.7%)
Smoking (pack year) 9.9 ± 7.5 9.8 ± 6.8 >.05
Table 2. BIS scores in heroin addicts and controls.
Variables
Heroin addicts
(mean ± SD)
Controls
(mean ± SD) p
AI 15.4 ± 4.6 11.1 ± 3.3 <.001
MI 22.6 ± 8.7 15.2 ± 4.9 <.001
UI 25.6 ± 9.4 17.9 ± 6.2 <.001
Total impulsivity 63.5 ± 21.8 44.3 ± 13.4 <.001
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Discussion
GDNF plays a crucial role in maintenance and survival
of adult dopamine neurons [22] and it has an impor-
tant protective effect in abstinence and relapse pro-
cesses of addiction.
We found that serum GDNF levels are significantly
lower in heroin addicts compared to healthy controls
and serum GDNF levels were inversely correlated
with both daily dosage of used heroin and duration
of addiction.
There is limited data about GDNF levels in heroin
addicts in literature. It is found that a GDNF genotype
was associated with a significantly increased risk for
heroin dependence [23].
Besides, GDNF has been the subject of research for
many chronic and neurodegenerative diseases. It is
reported that GDNF was significantly lower in patients
with Major Depressive Disorder (MDD) and Mood
Disorders (MD) compared to healthy controls [24]
and also patients with MD in a manic or depressive epi-
sode had lower GDNF levels compared to euthymic
MD patients [25].
GDNF was found to be associated with alcohol con-
sumption [26], addiction [27], and Parkinson’s disease
[28].
Kotyuk et al. reported [29] an association between a
genetic variant of GDNF (rs3096140) and smoking
behaviour.
In a recent study [30], it was found that GDNF regu-
lates dopamine transporter functioning in the striatum
and reducing or deleting GDNF is associated with
amphetamine-induced behaviour. These data suggest
endogenous GDNF plays a crucial role in addiction
and many other neuropsychiatric conditions.
Besides, GDNF genes were studied in patients with
schizophrenia based on the neurodevelopmental
ethio-pathogenesis of the disease and it is suggested
that the GDNF gene may have an involvement in the
genetic liability to Schizophrenia [31].
GDNF was also found to affect synaptic and struc-
tural plasticity [32]. Future studies may focus on the
role of neurotrophic factors in drug-induced synaptic
plasticity changes that potentially contribute to drug
abuse and addiction.
We found an association between serum GDNF
levels and both daily dosage of used heroin and
duration of addiction but it is not clear that the lower
levels of GDNF are a cause or result in heroin
addiction.
In our study, total impulsivity scores and scores of
AI, MI, and UI subscales were significantly higher in
heroin addicts compared to healthy controls; and
lower GDNF levels of heroin addicts were associated
with increased impulsivity. We also found that lower
levels of serum GDNF are associated with higher
depression and anxiety scores.
It is reported that substance addicts are more impul-
sive [33,34], but the mechanism of this impulsivity is
not clear. Our findings support the neurobiological
aetiology of the impulsivity in heroin addicts.
Our study was a cross-sectional, case-control study
and it cannot explain the cause-and-effect relationship
between addiction and GDNF. Besides, significantly
lower GDNF levels and its association with impulsivity,
depression, and anxiety scores suggest a biological basis
of heroin addiction and there are still many unknowns
in this area.
It is reported that GDNF may facilitate or inhibit
drug-taking behaviours in different pathways accord-
ing to the drug type, addiction phase, and the brain
site [35]. Future studies should focus on effects of
GDNF in terms of different phases of addiction with
neuroimaging and advanced techniques.
Conclusions
One of the main regulator growth factor, GDNF levels
are significantly lower in heroin addicts. There is a sig-
nificant association between serum GDNF levels and
impulsivity, anxiety, and depression rates.
Neurotrophic factors such as GDNF affecting the
dopaminergic system seem to find a prominent place
among the target molecules in the treatment of heroin
addiction.
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